OCT Agreement and Precision Study

Inclusion criteria

for Normal Group

• Subjects 18 years of age or older on the date of informed consent
• Subjects able to understand the written informed consent and willing to Criteria participate as evidenced by signing the informed consent
• Subjects presenting at the site with normal eyes (eyes without pathology)
• lOPs 21mmHg bilaterally
• BCVA 20/40 or better (each eye)
• Both eyes must be free of eye disease

Exclusion criteria

for Normal Group

• Subjects unable to tolerate ophthalmic imaging
• Subject with ocular media not sufficiently clear to obtain acceptable OCT images
• HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT 'Outside Normal Limits' and/or PSD < 5%
• HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses> 33% or false positives> 25%, or false negatives> 25%
• Presence of any ocular pathology except for cataract
• Previous ocular surgery or laser treatment, other than uncomplicated refractive procedure or cataract surgery, performed within six months prior to study scanning
• Narrow angle
• History of leukemia, dementia or multiple sclerosis
• Concomitant use of hydroxychloroquine and chloroquine

Inclusion criteria

for Glaucoma Group

• Subjects 18 years of age or older on the date of informed consent
• Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
• Subjects presenting at the site with glaucoma
• BCVA 20/40 or better in the study eye
• HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT 'Outside Normal Limits' and/or PSD < 5% in the study eye

Exclusion criteria

for Glaucoma Group

• Subjects unable to tolerate ophthalmic imaging
• Subject with ocular media not sufficiently clear to obtain acceptable OCT images
• HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as fixation losses> 33% or false positives> 25%, or false negatives > 25% in the study eye
• Presence of any ocular pathology except glaucoma in the study eye
• Previous ocular surgery or laser treatment, other than uncomplicated refractive procedure or cataract surgery, performed within six months prior to study scanning in the study eye
• History of leukemia, dementia or multiple sclerosis
• Concomitant use of hydroxychloroquine and chloroquine

Inclusion criteria

for Retina Disease Group

• Subjects 18 years of age or older on the date of informed consent
• Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
• Subjects presenting at the site with retinal disease
• lOP<= 21mmHg in the study eye
• BCVA 20/400 or better in the study eye
• Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others

Exclusion criteria

for Retinal Disease Group

• Subjects unable to tolerate ophthalmic imaging
• Subject with ocular media not sufficiently clear to obtain acceptable OCT images
• Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g., cornea pathology) in the study eye
• Previous ocular surgery or laser treatment other than uncomplicated refractive procedure or cataract surgery, performed within six months prior to study scanning in the study eye
• Narrow angle in the study eye
• History of leukemia, dementia or multiple sclerosis
• Concomitant use of hydroxychloroquine and chloroquine